Ergos Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 61.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 61.00 Cr
as on 28-06-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -29.07%
(FY 2021)
- Profit -67.24%
(FY 2021)
- Ebitda 74.11%
(FY 2021)
- Net Worth -59.81%
(FY 2021)
- Total Assets -93.00%
(FY 2021)
About Ergos Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 61.00 Cr and a paid-up capital of Rs 61.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ergos Life Sciences Private Limited India are Chetan Chandwani as COMPANY SECRETARY and Sakti Chakraborty as Ceo. Sakti Chakraborty and Vinay Sapte serve as directors at the Company.
- CIN/LLPIN
U24303MH2017PTC292787
- Company No.
292787
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2017
- Date of AGM
11 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ergos Life Sciences?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chetan Chandwani | Company Secretary | 14-Feb-2023 | Current |
Sakti Chakraborty  | CEO | 01-Apr-2017 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sakti Chakraborty | Director and Ceo | 01-Apr-2017 | Current |
| Vinay Sapte | Director | 21-Mar-2017 | Current |
Financial Performance and Corporate Structure Insights of Ergos Life Sciences.
Ergos Life Sciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 29.07% decrease. The company also saw a substantial fall in profitability, with a 67.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 59.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ergos Life Sciences?
In 2022, Ergos Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maneesh Pharmaceuticals LimitedActive 39 years 4 monthsVinay Sapte and Chetan Chandwani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ergos Life Sciences?
Ergos Life Sciences has a workforce of 292 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ergos Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ergos Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
